Role of doxycycline post exposure prophylaxis in the prevention of sexually transmitted infections: a narrative review

Authors

  • Faraz Waheed Department of Medicine, Hayatabad Medical Complex, Peshawar, Pakistan
  • Amina Sher Department of Medicine, Khyber Medical College, Peshawar, Pakistan
  • Muniba Gul Department of Medicine, Hayatabad Medical Complex, Peshawar, Pakistan
  • Ulfat Nisa Department of Medicine, Khyber Teaching Hospital Peshawar, Pakistan
  • Afaq Saeed Department of Medicine, Khyber Teaching Hospital Peshawar, Pakistan

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20242695

Keywords:

Doxycyline, PEP, STIs, Preventive medicine

Abstract

Sexually transmitted infections (STIs) spread through sexual intercourse. They are caused by pathogens like Neisseria gonorrhoeae, Treponema pallidum, Chlamydia trachomatis, and Mycoplasma genitalium, and can be transmitted through direct contact or contact with genital secretions. Doxycycline is a second-generation tetracycline antibiotic with a broad antimicrobial spectrum, acting on intracellular and extracellular organisms. This review aims to explore the efficacy of doxycycline post-exposure prophylaxis (PEP) in the prevention and treatment of STIs. Some of the areas of uncertainty with the use of doxycycline PEP for STIs include the concern for developing antimicrobial resistance (AMR), the effect on the normal microbiome of the body, public acceptability, drug formulation and dosage and compliance issues. Recent clinical and observational studies have looked at using doxycycline PEP to reduce the transmission of STIs. This review aims to explore these studies to provide a comprehensive account of the current state of doxycycline PEP and its future prospects. We also look at the limitations and areas of improvement in using doxycycline PEP, opening avenues for future research. High-quality studies have shown that using doxycycline PEP can effectively reduce the transmission of STIs in a number of clinical trials as well as systematic reviews., making it a potential standard treatment for high-risk groups such as immunocompromised patients, individuals living with HIV, sex workers, and men who have sex with men (MSM).

Metrics

Metrics Loading ...

References

Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med. 1997;157(13):1421-8.

Choudhri Y, Miller J, Sandhu J, Leon A, Aho J. Infectious and congenital syphilis in Canada, 2010-2015. Can Commun Dis Rep. 2018;44(2):43-8.

Surveillance and disease data for syphilis. 2012. Available at: https://www.ecdc.europa.eu/en/ syphilis/surveillance-and-disease-data. Accessed on 14 June 2024.

National C in HE and CRAI of H and W. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2005. ATSIHEALTH. 2005. Available at: https://search.informit.org/doi/abs/10.3316/atsihealth.2240. Accessed on 16 April 2024.

Montaño MA, Dombrowski JC, Dasgupta S, Golden MR, Duerr A, Manhart LE, et al. Changes in Sexual Behavior and STI Diagnoses among MSM Initiating PrEP in a Clinic Setting. AIDS Behav. 2019;23(2):548-55.

Nguyen VK, Greenwald ZR, Trottier H, Cadieux M, Goyette A, Beauchemin M, et al. Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. AIDS Lond Engl. 2018;32(4):523-30.

Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis. 2018;67(5):676-86.

Tan KR, Magill AJ, Parise ME, Arguin PM. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg. 2011;84(4):517.

Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sexually Transm Dis. 2015;42(2):98-103.

Ellen JM, Hessol NA, Kohn RP, Bolan GA. An investigation of geographic clustering of repeat cases of gonorrhea and chlamydial infection in San Francisco, 1989-1993: evidence for core groups. J Infect Dis. 1997;175(6):1519-22.

Gunn RA, Fitzgerald S, Aral SO. Sexually transmitted disease clinic clients at risk for subsequent gonorrhea and chlamydia infections: possible ‘core’ transmitters. Sexually Transm Dis. 2000;27(6):343-9.

Kong FYS, Kenyon C, Unemo M. Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections. J Antimicrob Chemother. 2023;78(7):1561-8.

Truong R, Tang V, Grennan T, Tan DH. A systematic review of the impacts of oral tetracycline class antibiotics on antimicrobial resistance in normal human flora. JAC-antimicrobial resistance. 2022;4(1):dlac009.

Cornelisse VJ, Ong JJ, Ryder N, Ooi C, Wong A, Kenchington P, et al. Interim position statement on doxycycline post-exposure prophylaxis (Doxy-PEP) for the prevention of bacterial sexually transmissible infections in Australia and Aotearoa New Zealand-the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Sexual Health. 2023;20(2):99-104.

Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Eng J Med. 2023;388(14):1296-306.

Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308-17.

Molina JM, Bercot B, Assoumou L, Michele IG, Rubenstein E, Pialoux G, et al. ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs in MSM on PrEP. In Conference on Retroviruses and Opportunistic Infections (CROI) 2023;19-22.

San Francisco Department of Public Health. Health Update: Doxycycline Post-exposure Prophylaxis Reduces Incidence of Sexually Transmitted Infections. 2022. Available at: https://www.sfcdcp. org/wp-content/uploads/2022/10/Health-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf. Accessed on 14 April 2024.

Hornuss D, Mathé P, Usadel S, Zimmermann S, Müller M, Rieg S. Already current practice? A snapshot survey on doxycycline use for prevention of sexually transmitted infections in parts of the German MSM community. Infection. 2023;51(6):1831-4.

Roster KI, Grad YH. Estimating changes in antibiotic consumption with the introduction of doxycycline post-exposure prophylaxis in the United States. MedRxiv. 2023.

Wormser GP, Warshafsky S, Visintainer P. Aggregation of data from 4 clinical studies demonstrating efficacy of single-dose doxycycline postexposure for prevention of the spirochetal infections: Lyme disease, syphilis, and tick-borne relapsing fever. Diagnost Microbiol Infect Dis. 2021;99(4):115293.

Bachmann LH. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR. Recommendations Rep. 2024;73(2):1-8.

Downloads

Published

2024-09-23

Issue

Section

Review Articles